Medvi vs Brello: GLP-1 Program Models and Pricing Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education.

Full head-to-head: PlexusDx vs MEDVi →

This is an independent editorial analysis. PlexusDx holds no commercial relationship with Medvi or Brello, earns nothing from affiliate links, and was not compensated for it.

Medvi and Brello land in the same lane: telehealth wrapped around a compounding-pharmacy supply of GLP-1 medications. When two programs look this similar on paper, the useful comparison is about oversight, dispensing pathway, and terms. Here is a fair-balance read as of April 2026.

Medvi and Brello side by side

Both brands share the core telehealth-plus-503A architecture, so the differences are in the details rather than the concept. Evaluating them means looking at provider type, pharmacy partner, subscription structure, and how transparently each publishes its terms — not at any claimed advantage in the underlying drug.

How Medvi structures its program

Medvi (Medvi Wellness) operates telehealth combined with compounded pharmacy. A licensed provider evaluates the patient, and eligible prescriptions are filled as branded FDA-approved GLP-1 products or compounded semaglutide or tirzepatide through a licensed 503A pathway. See its official website for current program details.

How Brello structures its program

Brello (Brello Health) uses the same telehealth-plus-compounding model, with program structure, medication options, and pricing that vary over time. Consult Brello's own site for current details when you read this. The operational sequence — intake, clinical review, prescription, fulfillment, follow-up — is consistent with the category.

Reading the price tag

Across the market in April 2026, monthly GLP-1 telehealth totals generally ran about $200 to $700 or more, reflecting program fees, medication, and compounded dispensing where applicable. Neither brand's number is fixed, and subscription length shifts the effective monthly cost. Confirm current pricing at each brand's own page rather than relying on figures quoted elsewhere.

The trial evidence behind the compounds

The clinical record is a property of the molecule. Semaglutide's STEP program (NEJM, 2021), tirzepatide's SURMOUNT program (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024) define what these compounds do. GLP-1 receptor agonists and the GIP/GLP-1 dual agonist tirzepatide act identically whether Medvi or Brello dispenses them.

Transparency and terms

When two programs share an identical model, how plainly each states its terms becomes a real differentiator. Clear disclosure of provider type, pharmacy relationships, cancellation rules, and what happens between refills tells you more than any marketing claim. Read the fine print on both Medvi and Brello, since ambiguity in the terms often costs more than the sticker price. Ask specifically how each brand handles a missed shipment, a dose change, and an early cancellation, since those moments are where an identical-looking model quietly diverges in practice; the answers, far more than the advertised monthly figure, reveal which program actually respects your time and your money once you are actually enrolled as a patient.

The upstream genetics gap

Both programs prescribe without mapping the biology underneath. GLP1R, the receptor every GLP-1 compound targets, sits beside FTO, MC4R, and TCF7L2 as pathway-level markers of your metabolic baseline. They describe terrain, not drug response. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights. PlexusDx also offers the medications through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — and the test does not predict response to any specific medication.

Independence note: PlexusDx is not affiliated with Medvi or Brello; this review is education only.

More reading: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, and GLP 1 What Is.

Editorial disclaimer: This comparison is educational. PlexusDx has no tie to Medvi or Brello but sells semaglutide and tirzepatide through its own protocols, so treat it as a disclosed viewpoint. The Precision Peptide Genetic Test maps gene-pathway influences and does not predict medication response. Consult a qualified provider before starting any protocol.

Consider the PlexusDx path: browse the Weight Management Protocols, or start with the Precision Peptide Genetic Test.

Frequently Asked Questions

How do I judge whether Medvi or Brello is trustworthy?

Look for licensed clinicians, a state-licensed or 503A pharmacy pathway, clinical evaluation before any prescription, and clear published terms. Both brands operate in the same regulated model, so verify credentialing and dispensing specifics on each company's own site rather than assuming one is inherently safer.

Are compounded medications from these programs legitimate?

Compounded semaglutide or tirzepatide is prepared by a licensed 503A compounding pharmacy under a prescription, which is a lawful pathway distinct from an FDA-approved finished drug. A prescriber decides whether it fits a patient. Confirm the pharmacy relationship each brand uses before enrolling.

What does PlexusDx add that these programs do not?

PlexusDx pairs the same compounds with the Precision Peptide Genetic Test, mapping pathway-level variants in FTO, and related genes. That upstream context is the difference, though it never predicts how you will respond to a specific medication or which program to choose.

Continue learning at the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.